| Tertiary lymphoid structures and B cells: An intratumoral immunity cycle WH Fridman, M Meylan, G Pupier, A Calvez, I Hernandez, ... Immunity 56 (10), 2254-2269, 2023 | 47 | 2023 |
| Molecular and clinical diversity in primary central nervous system lymphoma I Hernández-Verdin, E Kirasic, K Wienand, K Mokhtari, S Eimer, ... Annals of Oncology 34 (2), 186-199, 2023 | 30 | 2023 |
| Low-intensity pulsed ultrasound-mediated blood-brain barrier opening increases anti-programmed death-ligand 1 delivery and efficacy in Gl261 mouse model MH Ahmed, I Hernández-Verdin, E Quissac, N Lemaire, C Guerin, ... Pharmaceutics 15 (2), 455, 2023 | 12 | 2023 |
| Tracking the genetic susceptibility background of B-cell non-Hodgkin’s lymphomas from genome-wide association studies I Hernández-Verdin, K Labreche, M Benazra, K Mokhtari, K Hoang-Xuan, ... International journal of molecular sciences 22 (1), 122, 2020 | 10 | 2020 |
| Prognostic factors in primary central nervous system lymphoma A Morales-Martinez, L Nichelli, I Hernandez-Verdin, C Houillier, ... Current Opinion in Oncology 34 (6), 676-684, 2022 | 7 | 2022 |
| Recent advances in the diagnosis and the treatment of primary CNS lymphoma A Rachdi, H Hernandez-Tost, D Herzi, A Morales-Martinez, ... Revue Neurologique 179 (5), 481-489, 2023 | 6 | 2023 |
| Expression and prognostic value of CD80 and CD86 in the tumor microenvironment of newly diagnosed glioblastoma MH Ahmed, I Hernández-Verdin, F Bielle, M Verreault, J Lerond, ... Canadian Journal of Neurological Sciences 50 (2), 234-242, 2023 | 6 | 2023 |
| Spatial and Ecological Factors Modulate the Incidence of Anti-NMDAR Encephalitis—A Systematic Review A Alentorn, G Berzero, H Alexopoulos, J Tzartos, G Reyes Botero, ... Biomedicines 11 (6), 1525, 2023 | 3 | 2023 |
| Primary central nervous system lymphoma: advances in its pathogenesis, molecular markers and targeted therapies I Hernández-Verdin, A Morales-Martínez, K Hoang-Xuan, A Alentorn Current Opinion in Neurology 35 (6), 779-786, 2022 | 3 | 2022 |
| Pan-cancer landscape of AID-related mutations, composite mutations, and their potential role in the ICI response I Hernández-Verdin, KC Akdemir, D Ramazzotti, G Caravagna, ... NPJ Precision Oncology 6 (1), 89, 2022 | 3 | 2022 |
| CD80 and CD86: expression and prognostic value in newly diagnosed glioblastoma M Ahmed, I Hernández-Verdin, M Verreault, F Bielle, J Lerond, A Alentorn, ... Res Square, 2021 | 1 | 2021 |
| Treating central nervous system lymphoma in the era of precision medicine Y Garcilazo-Reyes, MJ Ibáñez-Juliá, I Hernández-Verdin, ... Expert Review of Precision Medicine and Drug Development 5 (4), 275-281, 2020 | 1 | 2020 |
| CYP2C9, CYP2D6, G6PD, GCLC, GSTM1 and NAT2 gene polymorphisms and risk of adverse reactions to sulfamethoxazole and ciprofloxacin in San Luis Potosí, Mexico E Hernández-Verdin, A Ganelón-Ríos, G Pettet-Ruiz, M Sánchez-Garza, ... Meta Gene 21, 100574, 2019 | 1 | 2019 |
| 1924P Targeting microenvironment and cellular immunity in sarcomas with trabectedin combined with metronomic cyclophosphamide: The TARMIC study CM Sun, I Hernandez, MS Ceruso, M Toulmonde, C Sautes-Fridman, ... Annals of Oncology 34, S1035, 2023 | | 2023 |
| Multi-Omics Analysis of Primary Central Nervous System Lymphoma I Hernández-Verdin Université Paris-Saclay, 2022 | | 2022 |
| Molecular and clinical diversity in primary central nervous system lymphoma: a LOC Network study A Alentorn, I Hernández-Verdin, E Kirasic, K Wienand, S Eimer, ... | | 2022 |
| Synthesis of Amine Terminated Pegylated Iron Oxide Nanoparticles for Prospective Astrocytoma Resection Grade Improvement IE Hernández-Verdin, ML Martínez, A Miranda-González, MA Sierra, ... Journal of Materials Science and Engineering A 9 (1-2), 25-37, 2019 | | 2019 |
| Polimorfismos de los genes CYP2C9, CYP2D6, G6PD y GCLC involucrados en el metabolismo de sulfametoxazol y ciprofloxacino: identificación basada en la secuenciación IE Hernández Verdin | | 2018 |
